Stocks of Allarity Therapeutics Inc (NASDAQ:ALLR) traded higher last session on Wall Street, down -13.99% to $0.50.
ALLR stock price is now -17.45% away from the 50-day moving average and -98.59% away from the 200-day moving average. The market capitalization of the company currently stands at $2.09M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
A total of 1.29% of the company’s stock is owned by insiders.
Wednesday’s opening bell rang with an opening price of $0.5134 for Allarity Therapeutics Inc (NASDAQ: ALLR). During the past 12 months, Allarity Therapeutics Inc has had a low of $0.45 and a high of $1890.00. The fifty day moving average price for ALLR is $0.6039 and a two-hundred day moving average price translates $35.4196 for the stock.
The latest earnings results from Allarity Therapeutics Inc (NASDAQ: ALLR) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$2.24, beating analysts’ expectations of -$8.17 by 5.93. This compares to -$702.78 EPS in the same period last year. The company reported revenue of $4.43 million for the quarter, compared to $4.56 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.98 percent.
Allarity Therapeutics Inc(ALLR) Company Profile
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
